The Evolving Landscape of Drug Innovation Funding: Government, Industry, and Non-Profits

This podcast episode delves into the complex ecosystem of drug development and funding, challenging conventional wisdom about the primary drivers of pharmaceutical innovation. The speaker, Fred Lley, a professor at Bentley University with a background in medicine and biotech, argues that while the private sector excels at large-scale development and commercialization, the foundational basic science that underpins nearly all new drugs is overwhelmingly supported by government funding, particularly through the NIH. He highlights the historical model established after World War II, inspired by Vannevar Bush's "Endless Frontier" report, which emphasized public investment in basic research as a societal good, leading to breakthroughs like penicillin and countless modern cancer therapies. A key distinction made is between early-stage drug discovery and late-stage development. Lley asserts that the initial, high-risk investments in "originating" drugs and early trials primarily come from government, philanthropies, universities, and capital markets, which are often driven by the prospect of company acquisition rather than the eventual price of a drug not yet discovered. In contrast, large pharmaceutical companies fund their extensive late-stage R&D (18-20% of revenues) for regulatory approval, market expansion, and new formulations. The episode explicitly challenges the assumption that reducing drug prices, as with the Inflation Reduction Act, would significantly stifle early innovation, suggesting that market forces like demographic access (e.g., Medicare Part D) are more direct drivers of industry investment in specific market segments. The discussion then pivots to a critical market failure: "diseases of poverty" or neglected tropical diseases. These conditions, prevalent in developing nations but also in impoverished pockets of the US and Europe, offer little lucrative return for for-profit companies despite their immense social burden. Lley presents the non-profit model, exemplified by the TB Alliance, as a viable alternative. This organization functions like a high-end biotech company, developing effective drugs like pretomanid entirely with government and philanthropic funds, bypassing the need for commercial revenues. However, this model faces challenges in sustainability, requiring continuous external funding and navigating historical distrust between public health and private enterprise. Broader implications include the need for carefully crafted, evidence-based policies that account for non-profit enterprises alongside the private sector, moving beyond tax-break incentives that don't benefit non-profits. The episode also touches on the transformative potential of AI in accelerating drug discovery and development, aiming to reduce the current 90% failure rate of promising scientific ideas in human trials. Ultimately, the podcast advocates for a diversified approach to drug innovation, recognizing the distinct strengths and limitations of government, for-profit industry, and non-profit organizations, and emphasizing the public good derived from sustained investment in basic science.

investments in basic science are going to really bear tremendous fruit for for the public for society and for the economy

most of what we know about cancer and how we can enable cancer cells to die and about half of the drugs come to market now for cancer therapy come from those studies

of the 387 drugs we looked at 99.6% of them we could identify NIH funded basic science which was essential for approval of that drug

for every dollar the government invests in that research private Enterprise invests about $2 or $3

we don't see any direct relationship between drug prices and investments in Innovation when we look back at at uh Market data over the last several decades

that Innovation Capital the first capital comes from government that's that early enabling investment coming from the NIH some from philanthropies some from universities but that next TR for investment is largely coming from Capital markets

the problem here is the classic market failure if we're talking about diseases of poverty it's not going to be a lucrative investment

what differentiates a nonprofit is simply they don't distribute their revenues or their profits to shareholders

AI is going to change a lot of things here and one of them will certainly be drug development and Drug Discovery

90% of the best ideas the scientists have still fail when they're actually put into human subjects